Click image to zoom

Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

BAYEUX, FRANCE - OCTOBER 13: A view of Doliprane 1000g boxes placed in front of a computer screen displaying the Sanofi logo, in Bayeux, Calvados, France, on October 13, 2024. Sanofi, the world's fifth-largest pharmaceutical company, is divesting a portion of its business by selling its consumer healthcare division, Opella, which includes around a hundred of its consumer health products, to the American investment fund Clayton, Dubilier and Rice (CDandR) for over 15 billion euros. (Photo by Artur Widak/NurPhoto)

Photo ID	#11661391
Date Taken	13 October 2024
Location	N/A
Photographer	Artur Widak/NurPhoto
Category	Economy, Business and Finance
Copyright	© 2026 NurPhoto - Artur Widak/NurPhoto

Acquisition Agreement Assets Billion Brand Business Buyout CD&R Capital Clayton Clayton Dubilier & Rice Commercial Company Competition Consumer-products Corporate Deal Deal-structure Divestment Doliprane Dubilier Equity Europe Euros Exit Expansion Financial France Fund Global Growth Health Healthcare Industry Innovation Integration Investment-fund Market Medicine Merger Opella Over-the-counter Ownership Painkillers Portfolio Pricing Restructure Rice Sale Sanofi Strategy Synergy Transaction Transfer USA Valuation consumer investment move pharmaceutical products profit revenue strategic Bayeux France Doliprane Sanofi pharmaceutical company divesting business consumer healthcare division Opella consumer health products American investment fund Clayton Dubilier and Rice CDandR 15 billion euros sale acquisition investment healthcare medicine pharmaceuticals Calvados logo computer screen October 13 2024 Artur Widak NurPhoto transaction corporate strategy financial deal divestiture health sector global market business strategy.